“We remain on track to report topline results from the Phase 3 sunRIZE trial in congenital hyperinsulinism in December,” said Nevan Charles Elam, Chief Executive Officer and Founder of Rezolute (RZLT). “In tumor hyperinsulinism, following FDA alignment on our streamlined Phase 3 trial and with enrollment now underway, we expect to both complete enrollment and report topline data in the second half of next year. As we advance toward potential commercialization of ersodetug for the treatment of hyperinsulinism, we look forward to highlighting our progress at our investor event next week.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RZLT:
- RZLT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Promising Potential of Rezolute’s Lead Candidate Ersodetug in Addressing Unmet Medical Need in cHI
- Rezolute price target raised to $17 from $9 at Citizens JMP
- Promising Prospects for Rezolute: Buy Rating Backed by Innovative Lead Candidate and Favorable Market Conditions
- 3 ‘Strong Buy’ Small-Cap Stocks Set to Surge, According to Analysts